LP-211

Cat. No.: HY-111455
CAS No.: 1052147-86-0
Molecular Formula: C₃₀H₃₄N₄O
Molecular Weight: 466.62
Target: 5-HT Receptor
Pathway: GPCR/G Protein; Neuronal Signaling
Storage: Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro
DMSO: ≥ 106.6 mg/mL (228.45 mM)
* “≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>2.1431 mL</td>
<td>10.7154 mL</td>
<td>21.4307 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.4286 mL</td>
<td>2.1431 mL</td>
<td>4.2861 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.2143 mL</td>
<td>1.0715 mL</td>
<td>2.1431 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
LP-211 is a selective and blood−brain barrier penetrant 5-HT₇ receptor agonist, with a Kᵢ of 0.58 nM, with high selectivity over 5-HT₁A receptor (Kᵢ, 188 nM) and D₂ receptor (Kᵢ, 142 nM).

IC₅₀ & Target
Kᵢ: 0.58 nM (5-HT₇ receptor), 188 nM (5-HT₁A receptor), 142 nM (D₂ receptor)[¹]

In Vitro
LP-211 is a selective 5-HT₇ receptor agonist, with a Kᵢ of 0.58 nM, 324- and 245-fold selectivity over 5-HT₁A receptor (Kᵢ, 188 nM) and D₂ receptor (Kᵢ, 142 nM). LP-211 shows agonist properties with an EC₅₀ of 0.6 μM[¹].

In Vivo
LP-211 (10 mg/kg, i.p.) rapidly reaches the systemic circulation in the mouse, with mean C_max of 0.76 ± 0.32 μg/mL at 30 min[¹]. LP-211 (0.003-0.3 mg/kg, i.p.) significantly increases the micturition volume in a dose-dependent manner, and causes significant increases in voiding efficiency in spinal cord-injured (SCI) rats, and such effects can be completely reversed by SB-269970[²]. LP-211 (0.25 and 0.50 mg/kg i.p.) improves consolidation of chamber-shape memory in rats, resulting in significant novelty-induced hyperactivity and recognition[³].
**PROTOCOL**

**Kinase Assay** [1]

Binding of [3H]-LSD at rat cloned 5-HT7 receptor is performed in the assay. In 1 mL of incubation buffer (50 mM Tris, 10 mM MgCl2 and 0.5 mM EDTA, pH 7.4) are suspended 30 μg of membranes, 2.5 nM [3H]-LSD, LP-211 (6–9 concentrations). The samples are incubated for 60 min at 37°C. The incubation is stopped by rapid filtration on GF/A glass fiber filters (presoaked in 0.5% polyethyleneimine for 30 min). The filters are washed with 3 × 53 mL of ice-cold buffer (50 mM Tris, pH 7.4). Nonspecific binding is determined in the presence of 10 μM 5-CT. Approximately 90% of specific binding is determined under these conditions[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Administration** [3]

**Rats**

Thirty male adult Wistar rats (300–450 g) are assessed for novelty preference behavior after acute treatment (administered immediately after the training session and 24 h before the test session). After a 4 weeks' wash out, the rPDT is conducted to evaluate attraction from a greater/uncertain reward, with a sub-chronic treatment (five injections, immediately after sessions which follow the indifferent point). Food restriction, imposed by the experimenter through a limited quantity of food given at the end of each rPDT session, is applied to increase motivation to work for food delivery. All behavioral tests take place between 9:30 am and 4:00 pm. Rats are randomly assigned to treatment (LP-211 at 0.25 or 0.50 mg/kg i.p.) and control groups (injection volume 10 mL/kg; n = 10 per group). The brain penetrant 5-HT7R agonist LP-211 is dissolved in a vehicle solution of 1% dimethyl sulfoxide (DMSO) in saline (0.9% NaCl). Control group receives the vehicle strictly in the same conditions[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898       Fax: 609-228-5909       E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA